Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 112,323,168
  • Shares Outstanding, K 1,244,992
  • Annual Sales, $ 27,116 M
  • Annual Income, $ 5,665 M
  • EBIT $ 2,558 M
  • EBITDA $ 5,251 M
  • 60-Month Beta 0.17
  • Price/Sales 4.12
  • Price/Cash Flow 10.04
  • Price/Book 6.15

Options Overview Details

View History
  • Implied Volatility 25.84% ( -1.72%)
  • Historical Volatility 13.22%
  • IV Percentile 75%
  • IV Rank 53.61%
  • IV High 33.98% on 08/05/24
  • IV Low 16.44% on 12/05/23
  • Put/Call Vol Ratio 0.92
  • Today's Volume 24,056
  • Volume Avg (30-Day) 8,083
  • Put/Call OI Ratio 0.90
  • Today's Open Interest 250,234
  • Open Int (30-Day) 248,121

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 1.56
  • Number of Estimates 10
  • High Estimate 2.20
  • Low Estimate 1.15
  • Prior Year 1.72
  • Growth Rate Est. (year over year) -9.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
84.17 +8.94%
on 10/11/24
91.98 -0.32%
on 11/06/24
+7.10 (+8.39%)
since 10/04/24
3-Month
72.43 +26.59%
on 08/12/24
91.98 -0.32%
on 11/06/24
+17.50 (+23.59%)
since 08/06/24
52-Week
62.07 +47.72%
on 05/31/24
91.98 -0.32%
on 11/06/24
+10.55 (+13.00%)
since 11/06/23

Most Recent Stories

More News
Gilead Sciences (GILD) Q3 2024 Earnings Call Transcript

GILD earnings call for the period ending September 30, 2024.

GILD : 91.69 (+1.63%)
Gilead: Q3 Earnings Snapshot

Gilead: Q3 Earnings Snapshot

GILD : 91.69 (+1.63%)
S&P Futures Soar as Trump Wins U.S. Presidency, FOMC Meeting on Tap

December S&P 500 E-Mini futures (ESZ24) are trending up +2.24% this morning after Republican Donald Trump won the U.S. presidential election.

CVS : 61.61 (+11.33%)
CE : 92.44 (+1.58%)
EXAS : 54.72 (-23.48%)
SMCI : 22.70 (-18.05%)
NXPI : 231.38 (+3.00%)
BMW.D.DX : 69.520 (+1.76%)
DJT : 35.96 (+5.94%)
QLYS : 159.23 (+24.18%)
MELI : 2,117.30 (+1.31%)
NOVOB.C.DX : 730.550 (-2.61%)
TSLA : 288.53 (+14.75%)
GFS : 46.79 (+13.10%)
What's in Store for These 5 Drug & Biotech Stocks in Q3 Earnings?

The earnings season for the drug/biotech sector is now in its final lap, with some large biotech and generic drug companies due to report their third-quarter 2024 results this week.The remaining large...

NVO : 105.36 (-4.33%)
VTRS : 11.61 (unch)
TEVA : 17.43 (-7.14%)
GILD : 91.69 (+1.63%)
MRNA : 51.81 (-2.78%)
Option Volatility And Earnings Report For November 4 - 8

We have some important companies with Palantir, Super Micro computer, Block, Moderna, Qualcomm, Arista Networks, Gilead Sciences and Airbnb all set to report.

QCOM : 172.99 (+4.27%)
GILD : 91.69 (+1.63%)
FSLY : 8.16 (+6.39%)
MRNA : 51.81 (-2.78%)
AMZN : 207.09 (+3.80%)
PLTR : 55.53 (+8.61%)
BMY : 55.28 (-1.20%)
ANET : 423.12 (+4.44%)
AAPL : 222.72 (-0.33%)
SMCI : 22.70 (-18.05%)
MSTR : 257.81 (+13.17%)
ABNB : 140.91 (+2.24%)
Stocks Set for Muted Open With All Eyes on U.S. Presidential Election and Fed Meeting

December S&P 500 E-Mini futures (ESZ24) are down -0.02%, and December Nasdaq 100 E-Mini futures (NQZ24) are down -0.10% this morning as market participants awaited the outcome of one of the most closely...

CVS : 61.61 (+11.33%)
AAPL : 222.72 (-0.33%)
ANET : 423.12 (+4.44%)
NQZ24 : 20,943.25 (+0.24%)
STMPA.P.DX : 25.275 (+2.33%)
ABNB : 140.91 (+2.24%)
QCOM : 172.99 (+4.27%)
KEYS : 161.85 (+4.49%)
TLN : 192.13 (+1.26%)
WBD : 8.38 (+2.07%)
RBLX : 52.90 (+3.36%)
DUK : 113.63 (-0.39%)
3 Absurdly Cheap Stocks That Pay High Dividends

These stocks are trading at less than 15 times their expected future profits.

MRK : 100.73 (-0.91%)
NVS : 106.81 (-2.35%)
GILD : 91.69 (+1.63%)
3 Top Healthcare Stocks to Buy for Growth and Dividends

Investors seeking growth and dividend income in the healthcare sector may want to consider Eli Lilly, Gilead Sciences, and Amgen, which have delivered impressive returns and boast strong pipelines and...

UHS : 203.52 (-4.08%)
LLY : 776.38 (-3.68%)
GILD : 91.69 (+1.63%)
ISRG : 515.55 (+0.07%)
AMGN : 321.79 (+0.78%)
DVA : 147.07 (-0.01%)
Gilead Sciences’ Quarterly Earnings Preview: What You Need to Know

Gilead Sciences is scheduled to report its fiscal third-quarter earnings next month, and analysts anticipate a lower-double-digit drop in its EPS.

XLV : 148.04 (+0.13%)
$SPX : 5,929.04 (+2.53%)
GILD : 91.69 (+1.63%)
Gilead, MRK Report Data From Investigational Combination Study for HIV

Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational combination of islatravir and lenacapavir for the treatment of HIV.Data showed...

MRK : 100.73 (-0.91%)
ALNY : 273.01 (+2.91%)
GILD : 91.69 (+1.63%)
GSK : 35.90 (-3.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya,...

See More

Key Turning Points

3rd Resistance Point 93.76
2nd Resistance Point 92.87
1st Resistance Point 92.28
Last Price 91.69
1st Support Level 90.80
2nd Support Level 89.91
3rd Support Level 89.32

See More

52-Week High 91.98
Last Price 91.69
Fibonacci 61.8% 80.55
Fibonacci 50% 77.03
Fibonacci 38.2% 73.50
52-Week Low 62.07

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar